New Ray Medicine International Holding Limited (HKG:6108)

Hong Kong · Delayed Price · Currency is HKD

0.2010

-0.0010 (-0.50%)

Jul 31, 2026, 3:08 PM HKT

-49.75% (1Y)

Market Cap	40.32M -39.7%
Revenue (ttm)	130.37M +38.8%
Net Income	-20.07M
EPS	-0.12
Shares Out	200.62M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	94,400
Open	0.2010
Previous Close	0.2020
Day's Range	0.2010 - 0.2010
52-Week Range	0.1910 - 0.4650
Beta	-3.93
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About HKG:6108

New Ray Medicine International Holding Limited, an investment holding company, engages in distribution and trading of pharmaceutical and related products in the People’s Republic of China. Its pharmaceutical products include levocarnitine injection for the treatment of muscular dystrophy, cardiomyopathy, acute and chronic myocardial infraction, angina pectoris, and parenteral nutrition; thoymosin α1 for injection to treat hepatitis and impaired immunity, HBe antiogen-positive, decompensated liver cirrhosis, severe hepatitis, tumor relating hepa... [Read more]

Industry Pharmaceutical Retailers

Sector Healthcare

Founded 2001

Employees 31

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 6108

Full Company Profile

Financial Performance

In 2025, HKG:6108's revenue was 130.37 million, an increase of 38.78% compared to the previous year's 93.95 million. Losses were -20.07 million, -35.29% less than in 2024.

Financial Statements